Complete the following form to download your document.
Article
GLP-1 Ingredient and Supply Chain Solutions for Health and Nutrition
Exploring GLP-1 ingredients, formulations, and supply chain solutions for pharmaceuticals, nutraceuticals, food, and beverage manufacturers
GLP-1 receptor agonist (RA) therapies are reshaping both medicine and nutrition, but the implications for pharmaceutical teams and food brands are fundamentally different. GLP-1 medications were originally developed to regulate blood sugar levels in people with diabetes, but are now widely used for weight management, appetite control, and metabolic health. These qualities have created significant ripple effects that are extending beyond the pharmaceutical industry.
As their popularity grows, GLP-1 therapies are influencing not only medical and weight outcomes but also consumer behavior, food choices, ingredient demand, and product innovation across multiple industries. For pharmaceuticals, nutraceuticals, and food and beverage manufacturers, understanding these consumer shifts is essential to your brand's growth and market share.
Explore where it matters most for your business:
How GLP-1 therapies are reshaping health, nutrition and consumer demand
GLP-1 agonist medications are transforming the landscape of health and nutrition across Europe, offering a comprehensive approach to managing type 2 diabetes and obesity which are two of the continent’s most significant public health challenges. With 33 million Europeans living with diabetes¹ and 53% of adults classified as overweight or obese², the addressable population is substantial. Currently, an estimated 9-10 million European and UK adults are using GLP-1 therapies which is approximately 2% of the adult population. Figures project this will grow sharply as access widens, and oral formulations remove the injection barrier for many potential users³. The European weight loss drug segment alone is forecast to grow at a CAGR of 16.1% between 2025 and 2030⁴. Critically, European adoption today sits well below the US rate of approximately 12%³, meaning brands and manufacturers across the continent have a meaningful window to develop and position GLP-1 companion products ahead of the expected acceleration in uptake.
What makes this movement different from anything we’ve seen previously in the health sector is the cross-industry impact of GLP-1 medications. The GLP-1 era is driving a sustained, global behavioral shift and reshaping eating patterns, nutritional demands, and product expectations, which are expected to continue evolving for years to come.
Meeting the ingredient and supply chain challenges of GLP-1 growth
Navigating the GLP-1 market requires more than understanding today’s consumer trends. It requires access to the right ingredients, produced at the highest standards, supported by a reliable global and domestic supply chain.
With one of the world’s most diverse ingredient portfolios combined with a world-leading supply chain and distribution network, Ingredients + Specialties from Univar Solutions supports pharmaceutical, nutraceutical, and food and beverage manufacturers as they tailor products to the GLP-1 user market.
End-to-end ingredient solutions for GLP-1 markets
Whether you are tackling reformulation, supply chain, or sourcing challenges, we have the experience and logistical infrastructure to keep you moving forward in the competitive GLP-1 market and complementary markets.
Food and beverage ingredient solutions to nourish the unique needs of GLP-1 RA users:
GLP-1 therapies are reshaping consumer demand in food and beverage, with appetite suppression and smaller portions driving brands to rethink portion sizes, formulations, and ingredients.
Food and Beverage producers are reformulating to:
- Deliver high fibre and protein
- Enhance satiety and gut health
- Support balanced nutrition with vitamins and minerals
- Use healthy fats and low-glycemic sweeteners
Pharmaceutical and nutraceutical solutions for the production of GLP-1 RA medications and supplements:
In the pharmaceutical sector, the demand for GLP-1 RA medications has led to significant investment in R&D, driving innovation in delivery formats, and resulting in intense competition.
Manufacturers are focused on:
- Longer-acting formulations
- Advanced delivery technologies
- Consumer-friendly dosing formats
- Improved stability, scalability, and supply reliability
Lorem ipsum dolor sit amet, consectetur adipiscing elit
imperdiet proin fermentum leo vel orci porta non pulvinar neque laoreet suspendisse interdum consectetur libero id faucibus nisl tincidunt eget nullam non nisi est sit amet facilisis magna etiam tempor orci eu lobortis elementum nibh tellus molestie nunc non blandit massa enim nec dui nunc mattis enim ut tellus elementum sagittis vitae et leo duis ut diam quam nulla porttitor massa id neque aliquam vestibulum morbi blandit cursus risus at ultrices mi tempus imperdiet nulla malesuada pellentesque elit eget gravida cum sociis natoque penatibus et magnis dis parturient montes nascetur ridiculus mus mauris vitae ultricies leo integer malesuada nunc vel risus commodo viverra maecenas accumsan lacus vel facilisis volutpat est velit egestas dui id ornare arcu odio ut sem nulla pharetra diam sit amet nisl suscipit adipiscing bibendum est ultricies integer quis auctor elit sed vulputate mi sit amet mauris commodo quis imperdiet massa tincidunt nunc pulvinar sapien et ligula ullamcorper malesuada
“Lacus eros, suscipit at laoreet iaculis, ornare vitae leo. Aenean volutpat risus diam, nec fermentum magna blandit a. Nam mollis faucibus ante eu faucibus. Ut consequat sed nisl vel condimentum.”
Lorem ipsum dolor sit amet, consectetur adipiscing elit
imperdiet proin fermentum leo vel orci porta non pulvinar neque laoreet suspendisse interdum consectetur libero id faucibus nisl tincidunt eget nullam non nisi est sit amet facilisis magna etiam tempor orci eu lobortis elementum nibh tellus molestie nunc non blandit massa enim nec dui nunc mattis enim ut tellus elementum sagittis vitae et leo duis ut diam quam nulla porttitor massa id neque aliquam vestibulum morbi blandit cursus risus at ultrices mi tempus imperdiet nulla malesuada pellentesque elit eget gravida cum sociis natoque penatibus et magnis dis parturient montes nascetur ridiculus mus mauris vitae ultricies leo integer malesuada nunc vel risus commodo viverra maecenas accumsan lacus vel facilisis volutpat est velit egestas dui id ornare arcu odio ut sem nulla pharetra diam sit amet nisl suscipit adipiscing bibendum est ultricies integer quis auctor elit sed vulputate mi sit amet mauris commodo quis imperdiet massa tincidunt nunc pulvinar sapien et ligula ullamcorper malesuada
Customer value
- Aliquam lacus eros, suscipit at laoreet iaculis, ornare vitae leo.
- Aenean volutpat risus diam, nec fermentum magna blandit a.
- Nam mollis faucibus ante eu faucibus. Ut consequat sed nisl vel condimentum.
- Praesent nec lacus nisl. Ut ac tellus nisi.
- Mollis faucibus ante eu faucibus. Ut consequat sed nisl vel
Customer value
- Aliquam lacus eros, suscipit at laoreet iaculis, ornare vitae leo.
- Aenean volutpat risus diam, nec fermentum magna blandit a.
- Nam mollis faucibus ante eu faucibus. Ut consequat sed nisl vel condimentum.
- Praesent nec lacus nisl. Ut ac tellus nisi.
- Mollis faucibus ante eu faucibus. Ut consequat sed nisl vel
Customer value
- Aliquam lacus eros, suscipit at laoreet iaculis, ornare vitae leo.
- Aenean volutpat risus diam, nec fermentum magna blandit a.
- Nam mollis faucibus ante eu faucibus. Ut consequat sed nisl vel condimentum.
- Praesent nec lacus nisl. Ut ac tellus nisi.
- Mollis faucibus ante eu faucibus. Ut consequat sed nisl vel
Lorem ipsum dolor sit amet, consectetur adipiscing elit
imperdiet proin fermentum leo vel orci porta non pulvinar neque laoreet suspendisse interdum consectetur libero id faucibus nisl tincidunt eget nullam non nisi est sit amet facilisis magna etiam tempor orci eu lobortis elementum nibh tellus molestie nunc non blandit massa enim nec dui nunc mattis enim ut tellus elementum sagittis vitae et leo duis ut diam quam nulla porttitor massa id neque aliquam vestibulum morbi blandit cursus risus at ultrices mi tempus imperdiet nulla malesuada pellentesque elit eget gravida cum sociis natoque penatibus et magnis dis parturient montes nascetur ridiculus mus mauris vitae ultricies leo integer malesuada nunc vel risus commodo viverra maecenas accumsan lacus vel facilisis volutpat est velit egestas dui id ornare arcu odio ut sem nulla pharetra diam sit amet nisl suscipit adipiscing bibendum est ultricies integer quis auctor elit sed vulputate mi sit amet mauris commodo quis imperdiet massa tincidunt nunc pulvinar sapien et ligula ullamcorper malesuada
imperdiet proin fermentum leo vel orci porta
imperdiet proin fermentum leo vel orci porta non pulvinar neque laoreet suspendisse interdum consectetur libero id faucibus nisl tincidunt eget nullam non nisi est sit amet facilisis magna etiam tempor orci eu lobortis elementum nibh tellus molestie nunc non blandit
Share this post!
References
1. IDF Diabetes Atlas, 10th Edition (2025)
2. WHO Europe obesity data (2025)
3. ING Bank European GLP-1 food demand report (April 2026)
4. Grand View Research — European GLP-1 weight loss drugs market (January 2026)
You may also like
Title — Recommended character count: 100
Description – Max character count: 230 – Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad.
Learn moreTitle — Recommended character count: 100
Description – Max character count: 230 – Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad.
Learn moreTitle — Recommended character count: 100
Description – Max character count: 230 – Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad.
Learn more
